Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Summary on Jun 26, 2018

June 26, 2018 - By Sarah Holford

Theravance Biopharma, Inc. (NASDAQ:TBPH) Corporate Logo
During Q1 2018 the big money sentiment increased to 1.35. That’s change of 0.04, from 2017Q4’s 1.31. 6 investors sold all, 25 reduced holdings as Theravance Biopharma, Inc. ratio increased. 28 grew positions while 14 funds acquired positions. Funds hold 35.61 million shares thus 1.57% more from 2017Q4’s 35.06 million shares.
Tower Research Cap Limited Liability Co (Trc) holds 660 shs or 0% of its capital. Nj State Employees Deferred Compensation Plan has 34,142 shs for 0.15% of their capital. Alliancebernstein L P stated it has 0% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH). New York-based D E Shaw has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Fmr Limited Com holds 0.02% or 8.07M shs. The New York-based Millennium Management Lc has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Pub Employees Retirement Association Of Colorado holds 0% or 10,856 shs. Laurion Capital Management Limited Partnership invested in 281,055 shs or 0.05% of the stock. Tekla Cap Mgmt Llc stated it has 8,083 shs or 0.01% of all its holdings. Qs has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Barclays Public Ltd Com reported 11,825 shs. The California-based Schwab Charles Invest Inc has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Bank & Trust Of America De holds 0% or 35,978 shs. Dekabank Deutsche Girozentrale reported 24,000 shs or 0% of all its holdings. Manufacturers Life The owns 30,838 shs for 0% of their capital.

Theravance Biopharma, Inc. registered $556,864 net activity with 1 insider buy and 2 sales since May 18, 2018. 1,000 Theravance Biopharma, Inc. (NASDAQ:TBPH) shs with value of $22,540 were bought by MALKIEL BURTON G. GALA RENEE D sold $242,877 worth of Theravance Biopharma, Inc. (NASDAQ:TBPH) on Friday, May 18.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

In total 3 analysts cover Theravance Biopharma (NASDAQ:TBPH). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:TBPH) has 100% bullish analysts. 4 are the (NASDAQ:TBPH)’s ratings reports on Jun 26, 2018 according to StockzIntelligence Inc. In Thursday, February 8 report Leerink Swann maintained it with “Outperform” rating and $48 target. The company rating was maintained by Cantor Fitzgerald on Tuesday, February 27. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 8. On Thursday, March 29 Piper Jaffray initiated Theravance Biopharma, Inc. (NASDAQ:TBPH) with “Buy” rating. Listed here are Theravance Biopharma, Inc. (NASDAQ:TBPH) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0000 Maintain
29/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $45.0000 Initiate
27/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0 Maintain
08/02/2018 Broker: Leerink Swann Rating: Outperform Old Target: $45 New Target: $48 Maintain

Ticker’s shares touched $23.65 during the last trading session after 2.87% change.Theravance Biopharma, Inc. has volume of 218,376 shares. Since June 26, 2017 TBPH has declined 36.55% and is downtrending. The stock underperformed the S&P 500 by 49.12%.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics.The company has $1.30 billion market cap. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.Last it reported negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

There’s a substantial Theravance Biopharma, Inc. (NASDAQ:TBPH) news posted by It’s an item titled: “Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018” on June 06, 2018.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.